MindMed CEO to Present at J.P. Morgan Healthcare Conference on January 14, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2025
0mins
Source: Businesswire
- Key Conference Participation: MindMed CEO Rob Barrow will present at the J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026, showcasing the company's advancements in psychiatry, which is expected to attract investor interest.
- Clinical Trial Progress: The company plans to release three pivotal Phase 3 trial results in the upcoming year, targeting Generalized Anxiety Disorder and Major Depressive Disorder, potentially paving the way for future FDA submissions in these significant markets.
- Investor Engagement Opportunity: This conference provides MindMed with a meaningful opportunity to engage with the investment community, aiming to enhance the company's visibility in the biopharmaceutical sector and attract potential investments.
- Commitment to Innovation: MindMed is focused on developing innovative product candidates targeting neurotransmitter pathways to improve brain health, demonstrating the company's long-term strategic vision in the mental health treatment space.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MNMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MNMD
Wall Street analysts forecast MNMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNMD is 31.11 USD with a low forecast of 18.00 USD and a high forecast of 61.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 15.020
Low
18.00
Averages
31.11
High
61.00
Current: 15.020
Low
18.00
Averages
31.11
High
61.00
About MNMD
Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The Company plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. It also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Definium Appoints Roger Adsett to Board of Directors to Drive Growth
- Leadership Expansion: Definium Therapeutics announces the appointment of Roger Adsett to its Board of Directors, leveraging over 20 years of experience in biopharmaceuticals to drive the company's success in three anticipated Phase 3 trials in 2026.
- Strategic Optimization: Adsett's proven track record at Insmed, particularly in launching ARIKAYCE® and BRINSUPRI®, indicates he will provide valuable commercial execution capabilities to enhance Definium's market impact in mental health treatments.
- Commitment to Scientific Rigor: Adsett expressed admiration for Definium's commitment to scientific rigor in mental health, indicating his dedication to translating clinical research into valuable therapies, thereby strengthening the company's leadership position in the industry.
- Educational Background and Experience: With an MBA from the Wharton School at the University of Pennsylvania and a bachelor's degree in English and economics from Bucknell University, Adsett's extensive educational and professional background will provide robust support for Definium's strategic development.
Continue Reading
Jones Initiates Coverage on MindMed, Highlighting Potential of Psychedelics for Mental Health Treatment
Analyst Initiation: Jones Trading has initiated coverage of MindMed (MNMD), highlighting its potential to leverage trends in psychedelic neuropsychiatry, with a price target of $61 indicating a potential 359% return.
Clinical Data Expectations: Analyst Justin Walsh anticipates that positive clinical data from earlier trials will lead to favorable Phase III results for MindMed's lead asset, MM120, which targets generalized anxiety disorder (GAD) and major depressive disorder (MDD).
Market Perception: Despite significant year-to-date gains in MindMed's stock, Walsh believes the market is undervaluing the company's potential and overestimating risks, citing promising Phase 2b data showing substantial improvements in anxiety symptoms with MM120.
Future Developments: MindMed is also working on MM402, an MDMA-derived therapy for autism, and plans to release pivotal Phase III data in 2026, supported by a strong financial position following a $242.8 million financing round.
Continue Reading